よむ、つかう、まなぶ。
【参考１】診療の手引き・第9.0版 (71 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00416.html |
| 出典情報 | 「新型コロナウイルス感染症に係る予防接種の実施に関する手引き」の改訂について（2／10付 事務連絡）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
●新型コロナウイルス感染症（COVID-19） 診療の手引き・第 9.0 版 ●５ 薬物療法
・Gottleib RL，et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2021.
・Hammond J，et al. Oral nirmatrelvir for high-risk，nonhospitalized adults with Covid-19. N Engl J Med 2022.
・Kikuchi K，et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort
study. Ren Replace Ther 2021.
・Mozaffari E，et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of
in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis 2021.
・Pan H，et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 2020.
・Wong CKH, et al. Real-world effectiveness of molnupiravir and nirmatrevir plus ritonavir against mortality,
hospitalization, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed
SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 2022.
【中和抗体薬】
・Chen P，et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2020.
・Gupta A，et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med
2021.
・Levin MJ, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med 2022.
・Montgomery H, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early
outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Respir Med 2022.
・Levin MJ, et al. AZD7442 (tixagevimab-cilgavimab) for post-exposure prophylaxis of symptomatic COVID-19. Clin
Infect Dis 2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1，BA.4，and BA.5
subvariants. N Engl J Med 2022.
・Siemieniul RA，et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and
network meta-analysis. BMJ 2021.
・Weinreich DM，et al. REGN-COV2，a neutralizing antibody cocktail，in outpatients with Covid-19. N Engl J Med
2021.
・Weinreich DM，et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J
Med 2021.
【免疫抑制・調節薬】
・Horby PW，et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020.
・Kalil AC，et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2020.
・Marconi VC，et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19（COVBARRIER）: a randomised，double-blind，parallel-group，placebo-controlled phase 3 trial. Lancet Respir Med 2021.
・RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
randomized, controlled, open-label, platform trial. Lancet 2021.
・RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a
randomized, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022.
・WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between
administration of IL-6 antagonists and mortality among patients hospitalized or COVID-19: A meta-analysis. JAMA
2021.
・Stone JH，et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020.
【妊婦に対する薬物療法】
・国立成育医療研究センター妊娠と薬情報センター．【医療関係者向け】新型コロナウイルス感染症の主な治療薬の妊娠中の安
全性について（2022.12.15. 改訂）https://www.ncchd.go.jp/kusuri/covid19_yakuzai.html
・Burwick RM，et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019.
Clin Infect Dis 2021.
・Garneau WM, et al. Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir for
acute SARS-CoV-2 Infection. JAMA Netw Open 2022.
・Homer CS, et al. The National COVID-19 Clinical Evidence Taskforce: pregnancy and perinatal guidelines. Med J
Aust 2022.
・Jorgensen SC, et al. A review of COVID-19 therapeutics in pregnancy and lactation. Obstet Med 2022.
◀︎ CONTENTS
71
・Gottleib RL，et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2021.
・Hammond J，et al. Oral nirmatrelvir for high-risk，nonhospitalized adults with Covid-19. N Engl J Med 2022.
・Kikuchi K，et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort
study. Ren Replace Ther 2021.
・Mozaffari E，et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of
in-hospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis 2021.
・Pan H，et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 2020.
・Wong CKH, et al. Real-world effectiveness of molnupiravir and nirmatrevir plus ritonavir against mortality,
hospitalization, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed
SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 2022.
【中和抗体薬】
・Chen P，et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2020.
・Gupta A，et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med
2021.
・Levin MJ, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med 2022.
・Montgomery H, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early
outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Respir Med 2022.
・Levin MJ, et al. AZD7442 (tixagevimab-cilgavimab) for post-exposure prophylaxis of symptomatic COVID-19. Clin
Infect Dis 2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med
2022.
・Takashita E，et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1，BA.4，and BA.5
subvariants. N Engl J Med 2022.
・Siemieniul RA，et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and
network meta-analysis. BMJ 2021.
・Weinreich DM，et al. REGN-COV2，a neutralizing antibody cocktail，in outpatients with Covid-19. N Engl J Med
2021.
・Weinreich DM，et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J
Med 2021.
【免疫抑制・調節薬】
・Horby PW，et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020.
・Kalil AC，et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2020.
・Marconi VC，et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19（COVBARRIER）: a randomised，double-blind，parallel-group，placebo-controlled phase 3 trial. Lancet Respir Med 2021.
・RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
randomized, controlled, open-label, platform trial. Lancet 2021.
・RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a
randomized, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022.
・WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between
administration of IL-6 antagonists and mortality among patients hospitalized or COVID-19: A meta-analysis. JAMA
2021.
・Stone JH，et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020.
【妊婦に対する薬物療法】
・国立成育医療研究センター妊娠と薬情報センター．【医療関係者向け】新型コロナウイルス感染症の主な治療薬の妊娠中の安
全性について（2022.12.15. 改訂）https://www.ncchd.go.jp/kusuri/covid19_yakuzai.html
・Burwick RM，et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019.
Clin Infect Dis 2021.
・Garneau WM, et al. Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir for
acute SARS-CoV-2 Infection. JAMA Netw Open 2022.
・Homer CS, et al. The National COVID-19 Clinical Evidence Taskforce: pregnancy and perinatal guidelines. Med J
Aust 2022.
・Jorgensen SC, et al. A review of COVID-19 therapeutics in pregnancy and lactation. Obstet Med 2022.
◀︎ CONTENTS
71